Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes

Sara Krogh Hansen; Eva-Maria D Nielsen; Jakob Ek; Gitte Andersen; Charlotte Glümer; Bendix Carstensen; Peter Mouritzen; Thomas Drivsholm; Knut Borch-Johnsen; Torben Jørgensen; Torben Hansen; Oluf Pedersen

doi:10.1210/jc.2004-1942

Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes

Sara Krogh Hansen, Eva-Maria D Nielsen, Jakob Ek, Gitte Andersen, Charlotte Glümer, Bendix Carstensen, Peter Mouritzen, Thomas Drivsholm, Knut Borch-Johnsen, Torben Jørgensen, Torben Hansen, Oluf Pedersen

Forskningsenheden for Almen Praksis

44 Citations (Scopus)

Abstract

The separate and combined effects of the PPARG Pro(12)Ala polymorphism and the KCNJ11 Glu(23)Lys polymorphisms on risk of type 2 diabetes were investigated in relatively large-scale, case-control studies. Separate effects of the variants were examined among 1187/1461 type 2 diabetic patients and 4791/4986 middle-aged, glucose-tolerant subjects. The combined analysis involved 1164 type 2 diabetic patients and 4733 middle-aged, glucose-tolerant subjects. In the separate analyses, the K allele of the KCNJ11 Glu(23)Lys associated with type 2 diabetes (odds ratio, 1.19; P = 0.0002), whereas the PPARG Pro(12)Ala showed no significant association with type 2 diabetes. The combined analysis indicated that the two polymorphisms acted in an additive manner to increase the risk of type 2 diabetes, and we found no evidence for a synergistic interaction between them. Analysis of a model with equal additive effects of the two variants showed that the odds ratio for type 2 diabetes increased with 1.14/risk allele (P = 0.003). Together, the two polymorphisms conferred a population-attributable risk for type 2 diabetes of 28%. In conclusion, our results showed no evidence of a synergistic interaction between the KCNJ11 Glu(23)Lys and PPARG Pro(12)Ala polymorphisms, but indicated that they may act in an additive manner to increase the risk of type 2 diabetes.

Original language	English
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	90
Issue number	6
Pages (from-to)	3629-37
Number of pages	9
ISSN	0021-972X
DOIs	https://doi.org/10.1210/jc.2004-1942
Publication status	Published - 1 Jun 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1210/jc.2004-1942

Cite this

Hansen, S. K., Nielsen, E.-M. D., Ek, J., Andersen, G., Glümer, C., Carstensen, B., Mouritzen, P., Drivsholm, T., Borch-Johnsen, K., Jørgensen, T., Hansen, T., & Pedersen, O. (2005). Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 90(6), 3629-37. https://doi.org/10.1210/jc.2004-1942

Hansen, SK, Nielsen, E-MD, Ek, J, Andersen, G, Glümer, C, Carstensen, B, Mouritzen, P, Drivsholm, T, Borch-Johnsen, K, Jørgensen, T, Hansen, T & Pedersen, O 2005, 'Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes', Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 6, pp. 3629-37. https://doi.org/10.1210/jc.2004-1942

@article{50e6efcbef984e77b0c73cd8ead2df9e,

title = "Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes",

abstract = "The separate and combined effects of the PPARG Pro(12)Ala polymorphism and the KCNJ11 Glu(23)Lys polymorphisms on risk of type 2 diabetes were investigated in relatively large-scale, case-control studies. Separate effects of the variants were examined among 1187/1461 type 2 diabetic patients and 4791/4986 middle-aged, glucose-tolerant subjects. The combined analysis involved 1164 type 2 diabetic patients and 4733 middle-aged, glucose-tolerant subjects. In the separate analyses, the K allele of the KCNJ11 Glu(23)Lys associated with type 2 diabetes (odds ratio, 1.19; P = 0.0002), whereas the PPARG Pro(12)Ala showed no significant association with type 2 diabetes. The combined analysis indicated that the two polymorphisms acted in an additive manner to increase the risk of type 2 diabetes, and we found no evidence for a synergistic interaction between them. Analysis of a model with equal additive effects of the two variants showed that the odds ratio for type 2 diabetes increased with 1.14/risk allele (P = 0.003). Together, the two polymorphisms conferred a population-attributable risk for type 2 diabetes of 28%. In conclusion, our results showed no evidence of a synergistic interaction between the KCNJ11 Glu(23)Lys and PPARG Pro(12)Ala polymorphisms, but indicated that they may act in an additive manner to increase the risk of type 2 diabetes.",

author = "Hansen, {Sara Krogh} and Nielsen, {Eva-Maria D} and Jakob Ek and Gitte Andersen and Charlotte Gl{\"u}mer and Bendix Carstensen and Peter Mouritzen and Thomas Drivsholm and Knut Borch-Johnsen and Torben J{\o}rgensen and Torben Hansen and Oluf Pedersen",

year = "2005",

month = jun,

day = "1",

doi = "10.1210/jc.2004-1942",

language = "English",

volume = "90",

pages = "3629--37",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes

AU - Hansen, Sara Krogh

AU - Nielsen, Eva-Maria D

AU - Ek, Jakob

AU - Andersen, Gitte

AU - Glümer, Charlotte

AU - Carstensen, Bendix

AU - Mouritzen, Peter

AU - Drivsholm, Thomas

AU - Borch-Johnsen, Knut

AU - Jørgensen, Torben

AU - Hansen, Torben

AU - Pedersen, Oluf

PY - 2005/6/1

Y1 - 2005/6/1

N2 - The separate and combined effects of the PPARG Pro(12)Ala polymorphism and the KCNJ11 Glu(23)Lys polymorphisms on risk of type 2 diabetes were investigated in relatively large-scale, case-control studies. Separate effects of the variants were examined among 1187/1461 type 2 diabetic patients and 4791/4986 middle-aged, glucose-tolerant subjects. The combined analysis involved 1164 type 2 diabetic patients and 4733 middle-aged, glucose-tolerant subjects. In the separate analyses, the K allele of the KCNJ11 Glu(23)Lys associated with type 2 diabetes (odds ratio, 1.19; P = 0.0002), whereas the PPARG Pro(12)Ala showed no significant association with type 2 diabetes. The combined analysis indicated that the two polymorphisms acted in an additive manner to increase the risk of type 2 diabetes, and we found no evidence for a synergistic interaction between them. Analysis of a model with equal additive effects of the two variants showed that the odds ratio for type 2 diabetes increased with 1.14/risk allele (P = 0.003). Together, the two polymorphisms conferred a population-attributable risk for type 2 diabetes of 28%. In conclusion, our results showed no evidence of a synergistic interaction between the KCNJ11 Glu(23)Lys and PPARG Pro(12)Ala polymorphisms, but indicated that they may act in an additive manner to increase the risk of type 2 diabetes.

AB - The separate and combined effects of the PPARG Pro(12)Ala polymorphism and the KCNJ11 Glu(23)Lys polymorphisms on risk of type 2 diabetes were investigated in relatively large-scale, case-control studies. Separate effects of the variants were examined among 1187/1461 type 2 diabetic patients and 4791/4986 middle-aged, glucose-tolerant subjects. The combined analysis involved 1164 type 2 diabetic patients and 4733 middle-aged, glucose-tolerant subjects. In the separate analyses, the K allele of the KCNJ11 Glu(23)Lys associated with type 2 diabetes (odds ratio, 1.19; P = 0.0002), whereas the PPARG Pro(12)Ala showed no significant association with type 2 diabetes. The combined analysis indicated that the two polymorphisms acted in an additive manner to increase the risk of type 2 diabetes, and we found no evidence for a synergistic interaction between them. Analysis of a model with equal additive effects of the two variants showed that the odds ratio for type 2 diabetes increased with 1.14/risk allele (P = 0.003). Together, the two polymorphisms conferred a population-attributable risk for type 2 diabetes of 28%. In conclusion, our results showed no evidence of a synergistic interaction between the KCNJ11 Glu(23)Lys and PPARG Pro(12)Ala polymorphisms, but indicated that they may act in an additive manner to increase the risk of type 2 diabetes.

U2 - 10.1210/jc.2004-1942

DO - 10.1210/jc.2004-1942

M3 - Journal article

C2 - 15797964

SN - 0021-972X

VL - 90

SP - 3629

EP - 3637

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

IS - 6

ER -

Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this